Related Experiment Video
Updated: Jun 22, 2026
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
A gene-alteration profile of human lung cancer cell lines
Raquel Blanco1, Reika Iwakawa, Moying Tang
1Lung Cancer Group, Molecular Pathology Programme, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain.
Abstract:
Aberrant proteins encoded from genes altered in tumors drive cancer development and may also be therapeutic targets. Here we derived a comprehensive gene-alteration profile of lung cancer cell lines. We tested 17 genes in a panel of 88 lung cancer cell lines and found the rates of alteration to be higher than previously thought. Nearly all cells feature inactivation at TP53 and CDKN2A or RB1, whereas BRAF, MET, ERBB2, and NRAS alterations were infrequent. A preferential accumulation of alterations among histopathological types and a mutually exclusive occurrence of alterations of CDKN2A and RB1 as well as of KRAS, epidermal growth factor receptor (EGFR), NRAS, and ERBB2 were seen. Moreover, in non-small-cell lung cancer (NSCLC), concomitant activation of signal transduction pathways known to converge in mammalian target of rapamycin (mTOR) was common. Cells with single activation of ERBB2, PTEN, or MET signaling showed greater sensitivity to cell-growth inhibition induced by erlotinib, LY294002, and PHA665752, respectively, than did cells featuring simultaneous activation of these pathways, underlining the need for combined therapeutic strategies in targeted cancer treatments. In conclusion, our gene-alteration landscape of lung cancer cell lines provides insights into how gene alterations accumulate and biological pathways interact in cancer.
Insights
This study profiles gene alterations in 88 lung cancer cell lines, revealing frequent TP53 and CDKN2A/RB1 inactivation. Understanding these genetic landscapes is crucial for developing targeted lung cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Aberrant proteins from altered genes drive cancer and represent therapeutic targets.
- Comprehensive gene-alteration profiling is essential for understanding cancer development.
Purpose of the Study:
- To create a comprehensive gene-alteration profile of lung cancer cell lines.
- To investigate the accumulation patterns and pathway interactions of gene alterations in lung cancer.
- To assess the implications for targeted cancer therapies.
Main Methods:
- Analysis of 17 key genes across a panel of 88 lung cancer cell lines.
- Identification of gene alteration frequencies, preferential accumulation by histopathological type, and mutually exclusive events.
- Assessment of signal transduction pathway activation and sensitivity to targeted inhibitors.
Main Results:
- Found higher-than-expected gene alteration rates, with near-universal TP53 and CDKN2A/RB1 inactivation.
- Observed infrequent alterations in BRAF, MET, ERBB2, and NRAS.
- Identified preferential accumulation and mutually exclusive patterns of specific gene alterations (e.g., CDKN2A/RB1, KRAS/EGFR/NRAS/ERBB2).
- Concomitant activation of pathways converging on mammalian target of rapamycin (mTOR) was common in non-small-cell lung cancer (NSCLC).
- Single pathway activations (ERBB2, PTEN, MET) showed greater sensitivity to specific inhibitors than simultaneous activations.
Conclusions:
- The gene-alteration landscape of lung cancer cell lines provides critical insights into cancer biology.
- Understanding gene alteration accumulation and pathway interactions is key for effective targeted cancer treatments.
- Combined therapeutic strategies are necessary for treating lung cancer, especially when multiple pathways are activated.
